Skip to main content
Board of Directors
Innovation engine overview
Extracting microbial biodiversity
Screening for new activity
Active compound characterization
Technology platform overview
DEINOVE is pioneering the exploration of “microbial dark matter”
By revealing the metabolic potential of rare bacteria or still classified as uncultivable, the company tackles a global health and economic challenge:
DEINOVE invites its shareholders to "Investir Day" on November 23, 2021
The first stage of the Phase II clinical trial continues despite the COVID-19 pandemic in the U.S...
DEINOVE presents its financial results and the advancement of its programs for the first half of 2021
Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB)...
More press releases